IL-23 is required for the development of severe egg-induced immunopathology in schistosomiasis and for lesional expression of IL-17

被引:80
|
作者
Rutitzky, Laura I. [1 ]
Bazzone, Lindsey [1 ]
Shainheit, Mara G. [1 ]
Joyce-Shaikh, Barbara [2 ]
Cua, Daniel J. [2 ]
Stadecker, Miguel J. [1 ]
机构
[1] Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA
[2] Schering Plough Biopharma, Palo Alto, CA 94304 USA
来源
JOURNAL OF IMMUNOLOGY | 2008年 / 180卷 / 04期
关键词
D O I
10.4049/jimmunol.180.4.2486
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In infection with the trematode helminth Schistosoma mansoni, the severity of CD4 T cell-mediated hepatic granulomatous and fibrosing inflammation against parasite eggs varies considerably in humans and among mouse strains. In mice, either the natural high pathology, or high pathology induced by concomitant immunization with schistosome egg Ags (SEA) in CFA (SEA/CFA), results from a failure to contain a net proinflammatory cytokine environment. We previously demonstrated that the induction of severe immunopathology was dependent on the IL-12/IL-23 common p40 subunit, and correlated with an increase in IL-17, thus implying IL-23 in the pathogenesis. We now show that mice lacking the IL-23-specific subunit p19 are impaired in developing severe immunopathology following immunization with SEA/CFA, which is associated with a marked drop of IL-17 in the granulomas, but not in the draining mesenteric lymph nodes, and with a markedly suppressed SEA-specific IFN-gamma response regulated by a striking increase in IL-10. The granulomas are characterized by a significant reduction in Gr-1(+) cell recruitment and by alternative macrophage activation. Taken together, these results demonstrate that IL-23 per se is not necessary for the generation of IL-17-producing T cells, but is essential for the development of severe schistosome egg-induced immunopathology, and its absence cannot be overcome with other possible compensatory mechanisms.
引用
收藏
页码:2486 / 2495
页数:10
相关论文
共 50 条
  • [41] IL-23/IL-17与多发性硬化
    高杰
    娄季宇
    王金兰
    中国实用神经疾病杂志, 2009, 12 (09) : 35 - 36+48
  • [42] IL-23/IL-17 axis in spondyloarthritis-bench to bedside
    Siba P. Raychaudhuri
    Smriti K. Raychaudhuri
    Clinical Rheumatology, 2016, 35 : 1437 - 1441
  • [43] New Biologics in Psoriasis: An Update on IL-23 and IL-17 Inhibitors
    Dong, Joanna
    Goldenberg, Gary
    CUTIS, 2017, 99 (02): : 123 - 127
  • [44] Detection of IL-17 and IL-23 in plasma samples of children with autism
    Department of Medical Microbiology and Immunology, M.I.N.D. Institute, University of California, Davis, CA, United States
    不详
    不详
    不详
    不详
    不详
    Am. J. Biochem. Biotechnol., 2008, 2 (114-120):
  • [45] IL-23/IL-17 axis in spondyloarthritis-bench to bedside
    Raychaudhuri, Siba P.
    Raychaudhuri, Smriti K.
    CLINICAL RHEUMATOLOGY, 2016, 35 (06) : 1437 - 1441
  • [46] Atherosclerotic lesions express mrna for IL-17, IL-17R, IL-23 and IL-23R
    De Oliveira, Romulo Tadeu Dias
    Momoni, Ronei Luciano
    Ferreira, Maria Carolina
    Longui, Larissa Nara Alegrini
    Souza, Jose Roberto Matos
    Fernandes, Juliano De Lara
    Menezes, Fabio Husenonan
    Blotta, Maria Heloisa
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (03) : 26 - 27
  • [47] IL-23/IL-17 in a Paradoxical Association with Primary Membranous Nephropathy
    Kaur, Prabhjot
    Prabhahar, Arun
    Pal, Deeksha
    Nada, Ritambhra
    Kohli, Harbir Singh
    Kumar, Vinod
    Ramachandran, Raja
    INFLAMMATION, 2024, 47 (04) : 1536 - 1544
  • [48] Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis
    Yang Mei
    Faming Pan
    Jing Gao
    Rui Ge
    Zhenhua Duan
    Zhen Zeng
    Fangfang Liao
    Guo Xia
    Sheng Wang
    Shengqian Xu
    Jianhua Xu
    Li Zhang
    Dongqing Ye
    Clinical Rheumatology, 2011, 30 : 269 - 273
  • [49] Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
    Hawkes, Jason E.
    Yan, Bernice Y.
    Chan, Tom C.
    Krueger, James G.
    JOURNAL OF IMMUNOLOGY, 2018, 201 (06): : 1605 - 1613
  • [50] The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis
    Joachim Sieper
    Denis Poddubnyy
    Pierre Miossec
    Nature Reviews Rheumatology, 2019, 15 : 747 - 757